P776: Polymeric exclusive enteral nutrition induces biochemical remission in adults with active Crohn's Disease irrespective of disease location or concomitant steroid useECCO’23 CopenhagenYear: 2023
Authors: Kuo, H.(1)*;Tognolini, K.(2);Willmann, L.(1);Haig, A.(1);Subhaharan, D.(1);Mutsekwa, R.(2);Shukla, D.(1);Moattar, H.(1);Dorrington, A.(1);Ishaq, N.(1);Bhullar, M.(1);Edwards, J.(1);Mohsen, W.(1);Kakkadasam Ramaswamy, P.(1);
(1)Gold Coast University Hospital, Department of Digestive Health, Gold Coast, Australia;(2)Gold Coast University Hospital, Department of Nutrition and Food Services, Gold Coast, Australia;Gold Coast Inflammatory Bowel Diseases Research Group
P777: Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sitesECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Weber, C.(3);Adsul, S.(4);Freire, M.(4);Biedermann, L.(5);Koelzer, V.(6);Bressler, B.(7);Xiong, W.(8);Niess, J.(9);Matthias Matter, M.M.(9);Kopylov, U.(10);Barshack, I.(11);Mayer, C.(11);Magro, F.(12);Carneiro, F.(13);Maharshak, N.(14);Greenberg, A.(15);Hart, S.(16);Dehmeshki, J.(17);Kubassova, O.(16);
(1)Nancy University Hospital, Gastroenterology, Nancy, France;(2)University of Chicago Medicine, Section of Gastroenterology- Hepatology and Nutrition, Chicago- IL, United States;(3)University of Chicago Medicine, Department of Pathology, Chicago- IL, United States;(4)Takeda, Takeda, Zurich, Switzerland;(5)University Hospital of Zurich, University of Zürich, Zurich, Switzerland;(6)University Hospital Zürich, Institute of Pathology and Molecular Pathology, Zurich, Switzerland;(7)University of British Columbia, Division of Gastroenterology, Vancouver- BC, Canada;(8)University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver- BC, Canada;(9)University of Basel, University Hospital Basel, Basel, Switzerland;(10)Chaim Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(11)Chaim Sheba Medical Center, Institute of Pathology, Ramat Gan, Israel;(12)Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal;(13)Centro Hospitalar Universitário de São João, Department of Pathology, Porto, Portugal;(14)Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;(15)Tel Aviv Medical Center, Institute of Pathology, Tel Aviv, Israel;(16)Image Analysis Group, Image Analysis Group, London, United Kingdom;(17)Image Analysis Group, Kingston University, London, United Kingdom;
P778: Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)ECCO’23 CopenhagenYear: 2023
Authors: García, M.J.(1)*;Riestra, S.(2);Amiot, A.(3);Julsgaard, M.(4);García de la Filia, I.(5);Calafat, M.(6);Aguas, M.(7);de la Peña, L.(8);Roig-Ramos, C.(9);Caballol, B.(10);Casanova, M.J.(11);Farkas, K.(12);Boysen, T.(13);Bujanda, L.(14);Cuarán, C.(15);Dobru, D.(16);Fousekis, F.(17);Gargallo-Puyuelo, C.J.(18);Savarino, E.(19);Calvet, X.(20);Huguet, J.M.(21);Kupcinskas, L.(22);López-Cardona, J.(23);Raine, T.(24);van Oostrom, J.(25);P. Gisbert*, J.(11);Chaparro*, M.(11);
(1)Hospital Universitario Marqués de Valdecilla- IDIVAL- Universidad de Cantabria, Gastroenterology and Hepatology, Santander- Cantabria, Spain;(2)Hospital Universitario Central de Asturias- Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(3)CHU Bicêtre- Universite Paris Saclay, Gastroenterology, Paris, France;(4)Aarhus University Hospital, Gastroenterology and Hepatology, Aarhus, Denmark;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitari Germans Trias i Pujol- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Barcelona, Spain;(7)La Fe University and Polytechnic Hospital- Health Research Institute La Fe, Gastroenterology, Valencia, Spain;(8)Bellvitge University Hospital, Gastroenterology, Barcelona, Spain;(9)Hospital de la Santa Creu i Sant Pau, Digestive Services, Barcelona, Spain;(10)Hospital Clinic- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Barcelona, Spain;(11)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(12)Universitary of Szeged, Medicine, Szeged, Hungary;(13)Medical Section- Copenhagen University Hospital Hvidovre, Gastrounit, Hvidovre, Denmark;(14)Biodonostia Health Research Institute- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad del País Vasco UPV/EHU, Gastroenterology, San Sebastián, Spain;(15)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(16)University of Medicine and Pharmacy- Science and Tehnology "G E Palade" Tg.Mures, Gastroenterology, Târgu-Mureș, Romania;(17)University Hospital of Ioannina, Gastroenterology, Ioannina, Greece;(18)University Clinic Hospital Lozano Blesa- Institute for Health Research Aragón IIS Aragón, Gastroenterology, Zaragoza, Spain;(19)Azienda Ospedale Università di Padova AOUP- Department of Surgery- Oncology and Gastroenterology DiSCOG- University of Padua, Gastroenterology, Padua, Italy;(20)Servei d'Aparell Digestiu. Corporació Sanitària Universitària Parc Taulí- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Instituto de Salud Carlos III- Universitat Autònoma de Barcelona, Gastroenterology, Sabadell, Spain;(21)General University Hospital of Valencia, Digestive Diseases, Valencia, Spain;(22)Institute for Digestive Research- Lithuanian University of Health Sciences, Gastroenterology, Kaunas, Lithuania;(23)Guy's and St Thomas' Hospital, IBD Unit, London, United Kingdom;(24)Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom;(25)Universitair Medische Centra UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;
P779: COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)ECCO’23 CopenhagenYear: 2023
Authors: Casellas Jorda, F.(1)*;Rodríguez, C.(2);Gisbert, J.P.(3);Bernardo, S.(4);Aparicio, J.(5);Tagarro, I.(5);Muñoz, F.(6);
(1)Hospital Universitari Vall d'Hebron, Crohn-Colitis Care Unit UACC, Barcelona, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain;(3)Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa IIS-Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd., Madrid, Spain;(4)Hospital de Santa Maria-Centro Hospitalar Lisboa Norte, Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal;(5)Takeda Farmacéutica España, Medical Department, Madrid, Spain;(6)Complejo Asistencial Universitario de Salamanca, Digestive Service, Salamanca, Spain;
P780: Prognosis and optimal treatment for 5-aminosalicylic acid-intolerant patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Yaguchi, K.(1,2)*;Kinoshita, H.(1);Kunisaki, R.(1,2);Madarame, A.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Hama, T.(1);Onishi, M.(1);Kobayashi, K.(1);Shibui, S.(1);Toritani, K.(1);Nishida, D.(1);Matsubayashi, M.(1);Nakamori, Y.(1);Nishio, M.(1);Umezawa, S.(1);Ogashiwa, T.(1);Sasaki, T.(1);Fujii, A.(1);Kimura, H.(1);Kato, J.(3);Maeda, S.(2);
(1)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan;(2)Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan;(3)Chiba University Graduate School of Medicine, Department of Gastroenterology, Chiba, Japan;
P781: Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING studyECCO’23 CopenhagenYear: 2023
Authors: Rubin, D.T.(1);Panés, J.(2);Torres, J.(3,4,5);Kobayashi, T.(6);Su, C.(7);Lawendy, N.(7);Modesto, I.(8);Segovia, M.(7,9);Gardiner, S.(8);Wang, W.(7);Vermeire, S.(10)*;
(1)-, University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago- IL, United States;(2)Formerly Department of Gastroenterology, Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain;(3)Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal;(4)Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;(5)Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal;(6)Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Toyko, Japan;(7)-, Pfizer Inc, Collegeville- PA, United States;(8)-, Pfizer Inc, New York- NY, United States;(9)-, Rutgers University, New Brunswick- NJ, United States;(10)Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;
P782: Ustekinumab in Ulcerative colitis: a real-life effectiveness study across multiple Belgian centers (SULTAN)ECCO’23 CopenhagenYear: 2023
Authors: Holvoet, T.(1)*;Truyens, M.(2);Reenaers, C.(3);Baert, F.(4);Vandenbranden, S.(5);Cremer, A.(6);Pouillon, L.(7);Dewint, P.(8);Van Moerkercke, W.(9);Rahier, J.F.(10);Vandermeulen, L.(11);Van Dongen, J.(12);Peeters, H.(13);Lambrecht, G.(14);Vijverman, A.(15);Lobaton, T.(16);
(1)VITAZ, Gastroenterology, Sint Niklaas, Belgium;(2)Ghent University Hospital, Gastroenterology, Ghent, Belgium;(3)CHU Liege, Gastroenterology, Liege, Belgium;(4)AZ Delta, Gastroenterology, Roeselaere, Belgium;(5)OLV Aalst, Gastroenterology, Aalst, Belgium;(6)Hôpital Erasme, Gastroenterology, Brussels, Belgium;(7)Imelda, Gastroenterology, Bonheiden, Belgium;(8)AZ Maria Middelares, Gastroenterlogy, Gent, Belgium;(9)AZ Groeninge, Gastroenterology, Kortrijk, Belgium;(10)CHU Namur, Gastroenterology, Namur, Belgium;(11)UZ Brussel, Gastroenterology, Brussel, Belgium;(12)AZ Sint Maarten, Gastroenterology, Mechelen, Belgium;(13)AZ Sint Lucas, Gastroenterology, Gent, Belgium;(14)AZ Damiaan, Gastroenterology, Oostende, Belgium;(15)CHR de la citadelle, Gastroenterology, Liege, Belgium;(16)Ghent University Hospital, Gastroenterology, Gent, Belgium;BIRD
P783: Symptom Improvement of ulceRative colitis after an Injection dose of Ustekinumab in Japanese clinical practice, measured using patient-reported outcomes (SIRIUS) study, Interim AnalysisECCO’23 CopenhagenYear: 2023
Authors: Matsuoka, K.(1)*;Katsumasa, N.(2);Murata, Y.(2);Hisamatsu, T.(3);
(1)Toho University Sakura Medical Center, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Sakura-city- Chiba, Japan;(2)Janssen Pharmaceutical K.K., Medical Affairs Division, Chiyoda-ku- Tokyo, Japan;(3)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Mitaka-city- Tokyo, Japan;SIRIUS study group
P784: Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD studyECCO’23 CopenhagenYear: 2023
Authors: Plachta-Danielzik, S.(1);Bokemeyer, B.(1,2,3)*;Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Ehehalt, R.(10);Trentmann, L.(11);Teich, N.(12);Atreya, R.(13);Franzenburg, S.(1);Hartmann, P.(4);Wenske, T.(1);Schreiber, S.(1,3);
(1)Competence network IBD, Study department, Kiel, Germany;(2)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis Centre, Minden, Germany;(3)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(4)Gastroenterology Practice Minden, Practice, Minden, Germany;(5)Center for Gastroenterology Saar MVZ, Practice, Saarbruecken, Germany;(6)Gastroenterology Practice Iserlohn, Practice, Iserlohn, Germany;(7)Gastroenterology Practice Kassel, Practice, Kassel, Germany;(8)Gastroenterology Practice Muenster, Practice, Muenster, Germany;(9)University Hospital Augsburg, III. medical clinic, Augsburg, Germany;(10)Gastroenterology Practice Heidelberg, Practice, Heidelberg, Germany;(11)Gastroenterology Practice Bremen, Practice, Bremen, Germany;(12)Gastroenterology Practice Leipzig, Practice, Leipzig, Germany;(13)Friedrich-Alexander-University Erlangen-Nuernberg, Medical Clinic 1, Erlangen, Germany;
P785: A retrospective cohort study on vedolizumab trough levels in Crohn's disease patientsECCO’23 CopenhagenYear: 2023
Authors: Pokryszka, J.(1)*;Stadlmann, M.(2);Primas, C.(3);Gerold, N.(3);Reinisch, S.(3);
(1)Department of Gastroenterology and Hepatology- Medical University of Vienna- Vienna- Austria, Department of Gastroenterology and Hepatology, Vienna, Austria;(2)Medical University of Viena, Department of Gastroenterology and Hepatology, Vienna, Austria;(3)Medical University of Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;
P786: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
(1)Hospital Clinic Barcelona- IDIPABS- CIBERehd, n/a, Barcelona, Spain;(2)University Hospital CHU of Liège, n/a, Liège, Belgium;(3)Imelda General Hospital, Imelda GI Clinical Research Centre, Bonheiden, Belgium;(4)AbbVie Inc., n/a, Chicago, United States;(5)Mayo Clinic College of Medicine and Science, n/a, Rochester, United States;
P787: Subcutaneous infliximab in IBD patients with previous immunogenic failure of intravenous infliximabECCO’23 CopenhagenYear: 2023
Authors: Husman, J.(1)*;Matthes, K.(1);Gilger, M.(1);Arsova, M.(1);Schmidt, A.(1);Hampe, J.(1);Zeißig, S.(1);Schmelz, R.(1);
(1)University Hospital Dresden- Technische Universität TU Dresden, Department of Medicine I, Dresden, Germany;
P788: Endoscopic management of patients with high-risk colorectal colitis-associated neoplasia: a Delphi studyECCO’23 CopenhagenYear: 2023
Authors: Bak, M.(1,2)*;Albéniz, E.(3);East, J.(4,5);Coelho-Prabhu, N.(6);Suzuki, N.(7);Saito, Y.(8);Matsumoto, T.(9);Banerjee, R.(10);Kaminski, M.(11);Kiesslich, R.(12);Coron, E.(13);de Vries, A.(14);van der Woude, C.J.(14);Bisschops, R.(15);Hart, A.(16);Itzkowitz, S.(17);Pioche, M.(18);Moons, L.(1);Oldenburg, B.(1);
(1)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)Erasmus University Medical Center Rotterdam, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(3)Hospital Universitario de Navarra HUN Navarrabiomed- Universidad Pública de Navarra UPNA- IdiSNA, Endoscopy Unit- Gastroenterology Department, Pamplona, Spain;(4)John Radcliffe Hospital- University of Oxford- and Oxford NIHR Biomedical Research Centre, Translational Gastroenterology Unit, Oxford, United Kingdom;(5)Mayo Clinic Healthcare, Division of Gastroenterology and Hepatology, London, United Kingdom;(6)Mayo Clinic, Department of Gastroenterology and Hepatology, Rochester- Minnesota, United States;(7)St Mark's Hospital and Academic Institute, Wolfson Unit for Endoscopy, Lodnon, United Kingdom;(8)National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan;(9)School of Medicine- Iwate Medical University, Division of Gastroenterology- Department of Internal Medicine, Morioka- Iwate, Japan;(10)Asian Institute of Gastroenterology, Inflammatory Bowel Disease Center, Hyderabad, India;(11)Medical Center for Postgraduate Education, Department of Gastroenterology- Hepatology and Oncology, Warsaw, Poland;(12)Helios Dr Horst Schmidt Kliniken Wiesbaden, Medical Director, Wiesbaden, Germany;(13)University Hospital of Geneva HUG, Department of Gastroenterology and Hepatology, Genève, Switzerland;(14)Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(15)University Hospitals Leuven- TARGID- KU Leuven-, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)St Mark's Hospital and Academic Institute, Department of Gastroenterology, London, United Kingdom;(17)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(18)Edouard Herriot Hospital- Hospices Civils de Lyon, Endoscopy and Gastroenterology Unit, Lyon, France;
P789: Inflammatory Bowel Disease subgroups identified by longitudinal faecal calprotectin profiles: A 10-year retrospective analysis of the Lothian IBD RegistryECCO’23 CopenhagenYear: 2023
Authors: Constantine-Cooke, N.(1,2)*;Monterrubio-Gómez, K.(1);Plevris, N.(3);Derikx, L.A.A.P.(4);Lyons, M.(3);Jenkinson, P.W.(3);Gros, B.(3);Jones, G.R.(5);Vallejos, C.A.(1,6);Lees, C.W.(2,3);
(1)University of Edinburgh, MRC Human Genetics Unit, Edinburgh, United Kingdom;(2)University of Edinburgh, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom;(3)Edinburgh IBD Unit, Edinburgh IBD Unit, Edinburgh, United Kingdom;(4)Radboud University Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(5)University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(6)The Alan Turing Institute, The Alan Turing Institute, London, United Kingdom;
P792: Pharmacokinetics and clinical evaluation of vedolizumab based on real-life routine monitoring data in IBD patientsECCO’23 CopenhagenYear: 2023
Authors: Markovic, S.(1)*;Kralj, D.(1);Odanovic, O.(1);Homšek, A.(2);Kalaba, A.(1);Svorcan, P.(1);Vučićević, K.(2);
(1)University Hospital Medical Center "Zvezdara", Gastroenterology and Hepatology Department, Belgrade, Serbia;(2)Faculty of Pharmacy – University of Belgrade- Republic of Serbia, Department of Pharmacokinetics and Clinical Pharmacy, Belgrade, Serbia;
P793: Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Wang, Z.(1)*;Afif , W.(2);Hanžel, J.(3,4);Kobayashi , T.(5);Papamichail , K.(6);Roblin , X.(7);Peyrin-Biroulet , L.(8);Vermeire , S.(9);Dreesen, E.(1);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)McGill University, Department of Medicine, Montreal, Canada;(3)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(4)University of Ljubljana, Department of Internal Medicine, Ljubljana, Slovenia;(5)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(6)Beth Israel Deaconess Medical Center, Division of Gastroenterology, Boston, United States;(7)University Hospital of Saint Etienne, Department of Gastroenterology, Saint Etienne, France;(8)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(9)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P794: Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center studyECCO’23 CopenhagenYear: 2023
Authors: Sakurai, K.(1)*;Katsurada, T.(1);Aoyama, K.(1);Fukushima, S.(1);Onishi, R.(1);Yagisawa, K.(2);Nishimura, H.(2);Ito, T.(2);Furukawa, S.(2);Maemoto, A.(2);Sakamoto, N.(1);
(1)Hokkaido University Hospital, Department of Gastroenterology and Hepatology, Sapporo City-Hokkaido, Japan;(2)Sapporo Higashi Tokushukai Hospital, Inflammatory Bowel Disease Center, Sapporo City-Hokkaido, Japan;
P795: Impact of anxiety and depression on inflammatory bowel disease patientsECCO’23 CopenhagenYear: 2023
Authors: SinaDr., M.(1)*;Pemaj, X.(1);Djegsi, A.(1);Telaku, S.(2);Osmanaj, D.(1);Babameto, A.(1);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)UBD, Gastroenterology, Pristina, Kosovo;
